Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

The anti-CD19 chimeric antigen receptor (CAR)–T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated tisagenlecleucel cellular kinetics with clinical/product parameters in 111 p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Awasthi, Rakesh, Pacaud, Lida, Waldron, Edward, Tam, Constantine S., Jäger, Ulrich, Borchmann, Peter, Jaglowski, Samantha, Foley, Stephen Ronan, van Besien, Koen, Wagner-Johnston, Nina D., Kersten, Marie José, Schuster, Stephen J., Salles, Gilles, Maziarz, Richard T., Anak, Özlem, del Corral, Christopher, Chu, Jufen, Gershgorin, Irina, Pruteanu-Malinici, Iulian, Chakraborty, Abhijit, Mueller, Karen Thudium, Waller, Edmund K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013261/
https://ncbi.nlm.nih.gov/pubmed/32045475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000525
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados